Hana Pharm. Co., Ltd.
Financials
Valuation Metrics
Hana Pharm. Co., Ltd.'s Market Cap is ₩1454B. At end of 2025 it was ₩1994B. Ranked #983 of 2,405 in KR market (top 41%), #499 of 778 on KOSPI (top 64%), #117 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 145.38B KRW | KR#983/2,405 Sec#117/231 |
| Revenue | 247.31B KRW | KR#920/2,405 Sec#51/231 |
| Net Income | 17.46B KRW | KR#753/2,405 Sec#50/231 |
| Total Assets | 446.69B KRW | KR#828/2,405 Sec#50/231 |
| Net Assets | 331.75B KRW | KR#683/2,405 Sec#45/231 |
| Employees | 730 | KR#346/2,405 Sec#29/231 |
| Value | ||
| P/E | 8.32x | KR#737/2,405 Sec#36/231 |
| P/B | 0.44x | KR#739/2,405 Sec#26/231 |
| P/S | 0.59x | KR#1,081/2,405 Sec#53/231 |
| EV/EBITDA | 6.98x | KR#427/2,405 Sec#18/231 |
| FCF Yield | 5.14% | KR#864/2,405 Sec#49/231 |
| Profitability | ||
| ROE | 5.26% | KR#1,070/2,405 Sec#73/231 |
| ROA | 3.91% | KR#893/2,405 Sec#72/231 |
| Op. Margin | 11.55% | KR#442/2,405 Sec#40/231 |
| Revenue Growth | 7.46% | KR#1,043/2,405 Sec#100/231 |
| Earnings Growth | -12.29% | KR#890/2,405 Sec#56/231 |
| Financial Health | ||
| Debt Ratio | 34.65% | KR#678/2,405 Sec#81/231 |
| Total Debt | 66.31B KRW | KR#893/2,405 Sec#61/231 |
| FCF | 7.47B KRW | KR#796/2,405 Sec#49/231 |
| Cash | 12.38B KRW | KR#1,561/2,405 Sec#128/231 |
| Current Ratio | 1.96x | KR#882/2,405 Sec#100/231 |
| Net Debt/EBITDA | 1.89x | KR#825/2,405 Sec#59/231 |
| Dividend | ||
| Div. Yield | 3.18% | KR#642/2,405 Sec#30/231 |
| Div. Growth | -49.02% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -28.93% | KR#1,385/2,405 Sec#103/231 |
| 1M Return | -2.62% | KR#503/2,405 Sec#48/231 |
| From 52W High | -31.83% | KR#463/2,405 Sec#30/231 |
| 1Y MDD | -32.47% | KR#312/2,405 Sec#22/231 |
| Trading | ||
| Volume | 17,412 shares | KR#1,568/2,405 Sec#154/231 |
| Trading Value | 141.8M KRW | KR#1,288/2,405 Sec#143/231 |
| Foreign Own. | 0.00% | KR—/2,405 Sec—/231 |
| Per Share | ||
| EPS | 983 KRW | KR#730/2,405 Sec#49/231 |
| BPS | 18,666 KRW | KR#560/2,405 Sec#37/231 |
Company Info
Established as Woocheon Pharmaceutical in 1973, this company changed its name to Hana Pharmaceutical in 1996 and was listed in 2018. It leads the market with strengths in narcotic analgesics and anesthetics, conducting specialty pharmaceutical businesses with over 380 health insurance-listed medicines. The company operates a manufacturing plant in Hwaseong, Gyeonggi-do, and an R&D center in Pangyo. It is expanding production through new injectable plant certification and focusing on developing biosimilars and DDS-based improved new drugs. Hana Pharmaceutical was founded in 1978 and is headquartered in Hwaseong-si, Gyeonggi-do.